Harwood Jared L, Alexander John H, Mayerson Joel L, Scharschmidt Thomas J
Department of Orthopaedics, The Ohio State University, 725 Prior Hall, 376 West 10 Avenue, Columbus, OH 43210, USA.
Department of Orthopaedics, The Ohio State University, 725 Prior Hall, 376 West 10 Avenue, Columbus, OH 43210, USA.
Orthop Clin North Am. 2015 Oct;46(4):587-608. doi: 10.1016/j.ocl.2015.06.011. Epub 2015 Aug 11.
Historically surgical intervention has been the mainstay of therapy for bone and soft-tissue sarcomas, augmented with adjuvant radiation for local control. Although cytotoxic chemotherapy revolutionized the treatment of many sarcomas, classic treatment regimens are fraught with side effects while outcomes have plateaued. However, since the approval of imatinib in 2002, research into targeted chemotherapy has increased exponentially. With targeted therapies comes the potential for decreased side effects and more potent, personalized treatment options. This article reviews the evolution of medical knowledge regarding sarcoma, the basic science of sarcomatogenesis, and the major targets and pathways now being studied.
从历史上看，手术干预一直是骨肉瘤和软组织肉瘤治疗的主要手段，并辅以辅助放疗以实现局部控制。尽管细胞毒性化疗彻底改变了许多肉瘤的治疗方式，但传统治疗方案副作用严重，且疗效已趋于平稳。然而，自2002年伊马替尼获批以来，针对靶向化疗的研究呈指数级增长。随着靶向治疗的出现，副作用减少以及更有效、个性化的治疗选择成为可能。本文回顾了关于肉瘤的医学知识演变、肉瘤发生的基础科学以及目前正在研究的主要靶点和途径。
